Inspire Medical Systems, Inc.
INSP · NYSE
Financial statements
Annual and quarterly income, balance-sheet, cash-flow and key-statistics data.
Income statement
| Period | Revenue | Gross profit | Operating income | Net income | EPS |
|---|---|---|---|---|---|
| 2022 FY | 407.86M | 341.74M | -47.59M | -44.88M | -1.60 |
| 2023 FY | 624.80M | 528.22M | -40.27M | -21.15M | -0.72 |
| 2024 FY | 802.80M | 679.82M | 36.08M | 53.51M | 1.80 |
| 2025 FY | 911.98M | 778.76M | 50.95M | 145.42M | 4.95 |
Balance sheet
| Period | Total assets | Liabilities | Cash | Debt | Equity |
|---|---|---|---|---|---|
| 2022 FY | 564.88M | 68.87M | 441.59M | 16.41M | 496.01M |
| 2023 FY | 676.81M | 104.30M | 185.54M | 24.85M | 572.51M |
| 2024 FY | 808.38M | 118.69M | 150.15M | 31.79M | 689.70M |
| 2025 FY | 907.32M | 126.16M | 104.81M | 32.16M | 781.16M |
Cash flow
| Period | Operating cash flow | Capital expenditure | Free cash flow | Dividends paid | Net cash change |
|---|---|---|---|---|---|
| 2022 FY | 11.57M | -9.10M | 2.47M | — | 227.13M |
| 2023 FY | 24.65M | -23.63M | 1.02M | — | -256.06M |
| 2024 FY | 130.25M | -39.12M | 91.12M | — | -35.39M |
| 2025 FY | 116.98M | -38.50M | 78.48M | — | -45.34M |
Key statistics
| Period | Market cap | Enterprise value | P/E | Price / sales | Debt / equity |
|---|---|---|---|---|---|
| 2022 FY | 7.07B | 6.65B | — | — | — |
| 2023 FY | 5.96B | 5.80B | — | — | — |
| 2024 FY | 5.52B | 5.40B | — | — | — |
| 2025 FY | 2.71B | 2.64B | — | — | — |
| 2026-12-31 | — | — | — | — | — |
| 2027-12-31 | — | — | — | — | — |
| 2028-12-31 | — | — | — | — | — |
Income statement
| Period | Revenue | Gross profit | Operating income | Net income | EPS |
|---|---|---|---|---|---|
| 2025 Q2 | 217.09M | 182.41M | -3.32M | -3.59M | -0.12 |
| 2025 Q3 | 224.50M | 192.73M | 9.64M | 9.93M | 0.34 |
| 2025 Q4 | 269.08M | 233.01M | 46.11M | 136.09M | 4.70 |
| 2026 Q1 | 204.58M | 176.91M | -1.12M | -11.29M | -0.39 |
Balance sheet
| Period | Total assets | Liabilities | Cash | Debt | Equity |
|---|---|---|---|---|---|
| 2025 Q2 | 802.19M | 124.38M | 106.93M | 33.06M | 677.81M |
| 2025 Q3 | 807.72M | 141.26M | 112.85M | 32.58M | 666.46M |
| 2025 Q4 | 918.49M | 137.33M | 104.81M | 62.15M | 781.16M |
| 2026 Q1 | 911.38M | 119.04M | 98.93M | 29.55M | 792.34M |
Cash flow
| Period | Operating cash flow | Capital expenditure | Free cash flow | Dividends paid | Net cash change |
|---|---|---|---|---|---|
| 2025 Q2 | 2.68M | -9.00M | -6.31M | — | 53.05M |
| 2025 Q3 | 68.53M | -10.44M | 58.09M | — | 5.92M |
| 2025 Q4 | 52.47M | -10.66M | 41.81M | — | -8.03M |
| 2026 Q1 | 12.85M | -9.73M | 3.12M | — | -5.88M |
Key statistics
| Period | Market cap | Enterprise value | P/E | Price / sales | Debt / equity |
|---|---|---|---|---|---|
| 2025 Q2 | 3.83B | 3.76B | — | — | — |
| 2025 Q3 | 2.18B | 2.10B | — | — | — |
| 2025 Q4 | 2.67B | 2.63B | — | — | — |
| 2026 Q1 | 1.48B | 1.41B | — | — | — |
| 2026-06-30 | — | — | — | — | — |
| 2026-09-30 | — | — | — | — | — |
| 2026-12-31 | — | — | — | — | — |